


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:


1. (Original) A compound of formula I:



or a pharmaceutically acceptable acid addition salt thereof, where;

R¹ is C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₃-C₇ cycloalkyl, substituted C₃-C₇ cycloalkyl, C₃-C₇ cycloalkyl-C₁-C₃ alkyl, substituted C₃-C₇ cycloalkyl-C₁-C₃ alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;

R² is hydrogen, C₁-C₃ alkyl, C₃-C₆ cycloalkyl-C₁-C₃ alkyl, or a group of formula II



II;

R³ is hydrogen or C₁-C₃ alkyl;

R⁴ is hydrogen, halo, or C₁-C₃ alkyl;

R⁵ is hydrogen or C₁-C₃ alkyl;

R⁶ is hydrogen or C₁-C₆ alkyl; and

n is an integer from 1 to 6 inclusively.


2. (Original) The compound Claim 1 wherein R⁵ is hydrogen and R⁴ is hydrogen or halogen.
3. (Original) The compound of Claim 2 wherein R⁴ is hydrogen.
4. (Original) The compound of any of Claims 1-3 wherein R² is hydrogen or C₁-C₃ alkyl.
5. (Previously Presented) The compound of Claim 1 wherein R¹ is phenyl, substituted phenyl, heterocycle, or substituted heterocycle.
6. (Currently Amended) The compound of Claim 1 wherein R¹ is phenyl, substituted phenyl, heterocycle or substituted heterocycle, wherein the heterocycle moiety is selected from the group consisting of furanyl, ~~thiophenyl~~thienyl, pyrrolyl, pyrrolidinyl, pyridinyl, N-methylpyrrolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, triazolyl, ozadiazolyl, thiadiazolyl, thiazolyl, thiazolidinyl, N-acetylthiazolidinyl, pyrimidinyl, pyrazinyl, pyridazinyl, isoquinolinyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, quinolinyl, benzofuranyl, benzothiophenyl, and indolyl, and wherein substituted is taken to mean the ring moiety is substituted with one to three halo substituents; or substituted with one to two substituents independently selected from the group consisting of halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, and C₁-C₄ alkylthio, wherein each alkyl, alkoxy and alkylthio substituent can be further substituted independently with C₁-C₂ alkoxy or with one to five halo groups each independently selected from fluoro and chloro; or substituted with one substituent selected from the group consisting of phenyloxy, benzyloxy, phenylthio, benzylthio, and pyrimidinyl, wherein the phenyloxy, benzyloxy, phenylthio, benzylthio, or pyrimidinyl moiety

can be further substituted with one to two substituents selected from the group consisting of halo, C₁-C₂ alkyl, and C₁-C₂ alkoxy; or substituted with one substituent selected from the group consisting of C₁-C₄ acyl and C₁-C₄ alkoxycarbonyl, and further substituted with zero to one substituent selected from the group consisting of halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, and C₁-C₄ alkylthio.

7. (Currently Amended) The compound of Claim 1 wherein R¹ is phenyl, substituted phenyl, heterocycle or substituted heterocycle, wherein the heterocycle moiety is selected from the group consisting of pyridinyl, indolyl, benzofuranyl, furanyl, ~~thiophenyl~~phenylthienyl, benzodioxolyl, and thiazolidinyl, and wherein substituted is taken to mean the ring moiety is substituted with one to three halo substituents; or substituted with one to two substituents independently selected from the group consisting of halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, and C₁-C₄ alkylthio, wherein each alkyl, alkoxy and alkylthio substituent can be further substituted independently with C₁-C₂ alkoxy or with one to five halo groups each independently selected from fluoro and chloro; or substituted with one substituent selected from the group consisting of phenyloxy, benzyloxy, phenylthio, benzylthio, and pyrimidinyl, wherein the phenyloxy, benzyloxy, phenylthio; or pyrimidinyl moiety can be further substituted with one to two substituents selected from the group consisting of halo, C₁-C₂ alkyl, and C₁-C₂ alkoxy; or substituted with one substituent selected from the group consisting of C₁-C₄ acyl and C₁-C₄ alkoxycarbonyl, and further substituted with zero to one substituent selected from the group consisting of halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, and C₁-C₄ alkylthio.

8. (Cancelled)


9. (Withdrawn) A method for activating 5-HT_{1F} receptors in a mammal comprising administering to a mammal in need of such activation an effective amount of compound of formula I:



or a pharmaceutically acceptable acid addition salt thereof, where;

R¹ is C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₃-C₇ cycloalkyl, substituted C₃-C₇ cycloalkyl, C₃-C₇ cycloalkyl-C₁-C₃ alkyl, substituted C₃-C₇ cycloalkyl-C₁-C₃ alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;

R² is hydrogen, C₁-C₃ alkyl, C₃-C₆ cycloalkyl-C₁-C₃ alkyl, or a group of formula II



R³ is hydrogen or C₁-C₃ alkyl;

R⁴ is hydrogen, halo, or C₁-C₃ alkyl;


R⁵ is hydrogen or C₁-C₃ alkyl;

R⁶ is hydrogen or C₁-C₆ alkyl; and

n is an integer from 1 to 6 inclusively.

10. (Withdrawn) The method according to Claim 9 wherein the mammal is a human.


11. (Withdrawn) A method for inhibiting neuronal protein extravasation in a mammal comprising administering to a mammal in need of such inhibition an effective amount of a compound of formula I:



or a pharmaceutically acceptable acid addition salt thereof, where;

R¹ is C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₃-C₇ cycloalkyl, substituted C₃-C₇ cycloalkyl, C₃-C₇ cycloalkyl-C₁-C₃ alkyl, substituted C₃-C₇ cycloalkyl-C₁-C₃ alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;

R² is hydrogen, C₁-C₃ alkyl, C₃-C₆ cycloalkyl-C₁-C₃ alkyl, or a group of formula II



R³ is hydrogen or C₁-C₃ alkyl;


R⁴ is hydrogen, halo, or C₁-C₃ alkyl;

R⁵ is hydrogen or C₁-C₃ alkyl;

R⁶ is hydrogen or C₁-C₆ alkyl; and

n is an integer from 1 to 6 inclusively.


12. (Withdrawn) The method according to Claim 11 wherein the mammal is a human.
13. (Withdrawn) A method for the treatment or prevention of migraine in a mammal comprising administering to a mammal in need of such treatment or prevention an effective amount of a compound of formula I:



or a pharmaceutically acceptable acid addition salt thereof, where;

R¹ is C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₃-C₇ cycloalkyl, substituted C₃-C₇ cycloalkyl, C₃-C₇ cycloalkyl-C₁-C₃ alkyl, substituted C₃-C₇ cycloalkyl-C₁-C₃ alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;

R² is hydrogen, C₁-C₃ alkyl, C₃-C₆ cycloalkyl-C₁-C₃ alkyl, or a group of formula II



R³ is hydrogen or C₁-C₃ alkyl;

R⁴ is hydrogen, halo, or C₁-C₃ alkyl;

R⁵ is hydrogen or C₁-C₃ alkyl;


R⁶ is hydrogen or C₁-C₆ alkyl; and

n is an integer from 1 to 16 inclusively.

14. (Withdrawn) The method according to Claim 13 wherein the mammal is a human.


15-26. (Cancelled)

27. (Withdrawn) A process for preparing a 2-halo-6-(piperidin-4-carbonyl)pyridine compound of formula III



where X is bromo or chloro;

R⁸ is an amino protecting group, C₁-C₃ alkyl, C₃-C₆ cycloalkyl-C₁-C₃ alkyl, or a group of formula II




R⁶ is hydrogen or C₁-C₆ alkyl; and

n is an integer from 1 to 6 inclusively;

comprising

- 1) reacting a 2,6-dihalopyridine selected from 2,6-dibromopyridine and 2,6-dichloropyridine, with n-butyl lithium to form 2-halo-6-lithium-pyridine, and then
- 2) reacting the 2-halo-6-lithium-pyridine with a substituted aminocarbonylpiperidine compound of formula IV



wherein R^9 and R^{10} are each methyl, or R^9 and R^{10} , together with the nitrogen to which they are attached, combine to form azetidiny, pyrrolidinyl, or piperidinyl.

28. (Withdrawn) The process of Claim 27 wherein X is bromo and the 2,6-dihalopyridine is 2,6-dibromopyridine.


29. (Withdrawn) The process of Claim 27 wherein R^9 and R^{10} are each methyl.

30. (Withdrawn) The process of Claim 27 wherein R^9 and R^{10} , together with the nitrogen to which they are attached, combine to form pyrrolidinyl.

31. (Withdrawn) The process of Claim 27 wherein the solvent for step 2) is methyl-*t*-butylether.


32. (Withdrawn) The process of Claim 27 wherein the solvent for step 2) is toluene.

33. (Withdrawn) A method for preparing a 2-bromo-6-(piperidin-4-carbonyl)pyridine compound of formula III



wherein R^7 is C_1 - C_3 n-alkyl, or an amino protecting group;

comprising reacting 2,6-dibromopyridine with n-butyl lithium to form 2-bromo-6-lithium-pyridine, and then reacting the 2-bromo-6-lithium-pyridine with a 4-(N,N'-dimethylamino)carbonyl piperidine compound of formula IV



in a methyl-*tert*-butyl ether solvent.

34. (Withdrawn) The process of Claim 28 wherein R⁹ and R¹⁰ are each methyl.
35. (Withdrawn) The process of Claim 28 wherein R⁹ and R¹⁰, together with the nitrogen to which they are attached, combine to form pyrrolidinyI.
36. (Withdrawn) The process of Claim 28 wherein the solvent for step 2) is methyl-*t*-butylether.
37. (Withdrawn) The process of Claim 29 wherein the solvent for step 2) is methyl-*t*-butylether.
38. (Withdrawn) The process of Claim 30 wherein the solvent for step 2) is methyl-*t*-butylether.
39. (Withdrawn) The process of Claim 34 wherein the solvent for step 2) is methyl-*t*-butylether
40. (Withdrawn) The process of Claim 35 wherein the solvent for step 2) is methyl-*t*-butylether.
41. (Withdrawn) The process of Claim 28 wherein the solvent for step 2) is toluene.
42. (Withdrawn) The process of Claim 29 wherein the solvent for step 2) is toluene.
43. (Withdrawn) The process of Claim 30 wherein the solvent for step 2) is toluene.
44. (Withdrawn) The process of Claim 34 wherein the solvent for step 2) is toluene.
45. (Withdrawn) The process of Claim 35 wherein the solvent for step 2) is toluene.
46. (Previously Presented) The compound of Claim 5 wherein R⁵ is hydrogen and R⁴ is hydrogen or halogen.
47. (Previously Presented) The compound of Claim 46 wherein R⁴ is hydrogen.

48. (Previously Presented) The compound of any one of Claims 5, 46, or 47 wherein R^2 is hydrogen or C_1-C_3 alkyl.
49. (Previously Presented) The compound of Claim 6 wherein R^5 is hydrogen and R^4 is hydrogen or halogen.
50. (Previously Presented) The compound of Claim 49 wherein R^4 is hydrogen.
51. (Previously Presented) The compound of any one of Claims 6, 49, or 50, wherein R^2 is hydrogen or C_1-C_3 alkyl.
52. (Previously Presented) The compound of Claim 7 wherein R^5 is hydrogen and R^4 is hydrogen or halogen.
53. (Previously Presented) The compound of Claim 52 wherein R^4 is hydrogen.
54. (Previously Presented) The compound of any of Claims 7, 52, or 53 wherein R^2 is hydrogen or C_1-C_3 alkyl.
55. (Previously Presented) A pharmaceutical formulation comprising a compound of any one of Claims 1-7, 46-54 and a pharmaceutical carrier, diluent, or excipient
56. (Previously Presented) The compound 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidiny)carbonyl]-2-pyridinyl]-benzamide or a pharmaceutically acceptable acid addition salt thereof.
57. (Previously Presented) The compound 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidiny)carbonyl]-2-pyridinyl]-benzamide hemisuccinate salt.
58. (Previously Presented) The compound 2, 4,6-trifluoro-N-[6-[(1-methyl-4-piperidiny)carbonyl]-2-pyridinyl]-benzamide hydrochloride salt.